Aaron Bao

Aaron Bao

Auto-generated profile, based on publicly available information

Aaron Bao

Department of Plastic and Reconstructive Surgery, The Johns Hopkins University School of Medicine , Baltimore, MD 21287

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2023 in Lupus Science & Medicine
Verified
Journal Article
Open access
PDF file
ABAaron Bao
Aaron Bao
MPMichelle A Petri
Michelle A Petri
AFAndrea Fava
Andrea Fava
JKJun Kang
Jun Kang
Objective: To assess the efficacy of anifrolumab, a type-1 interferon receptor subunit-1 monoclonal antibody, in treating refractory cutaneous lupus erythematosus (CLE) and lupus non-specific mucocutaneous manifestations in patients with systemic lupus erythematosus (SLE).Methods: A case series comprising four SLE patients with refractory CLE received anifrolumab (300mg) as add-on therapy. Medical history, serological markers and images were collected. Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) was assessed at baseline and post-treatment visits.Results: Patient 1:Anifrolumab effectively treated refractory chronic cutaneous lupus erythematosus with lupus panniculitis and calcinosis cutis.Patient 2:Anifrolumab demonstrated rapid improvement in generalised discoid lupus, achieving a substantial reduction in CLASI-A from 40 to 8.Patient 3:Switching from belimumab to anifrolumab led to notable improvement in photosensitivity and tumid lupus.Patient 4:Anifrolumab effectively managed refractory subacute cutaneous lupus erythematosus, resulting in remarkable cutaneous improvement and successful tapering of prednisone and mycophenolate mofetil.Conclusion: Anifrolumab demonstrates efficacy in treating refractory CLE subtypes and lupus non-specific mucocutaneous manifestations in SLE patients. Further studies are needed to establish response rates, optimal dosing, and long-term outcomes.

18 March 2025 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
ABAaron Bao
Aaron Bao
LBLindsey A. Bordone
Lindsey A. Bordone
CACrystal Aguh
Crystal Aguh

27 February 2025 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
ADAnjali J D’aMiano
Anjali J D’aMiano
YAYagiz Matthew Akiska
Yagiz Matthew Akiska
JKJack Kollings
Jack Kollings
ABAaron Bao
Aaron Bao
VMVrinda Madan
Vrinda Madan
SKShawn G. Kwatra
Shawn G. Kwatra
In this retrospective study, we investigated the role of baseline IgE levels in predicting the treatment response to dupilumab in patients with prurigo nodularis (PN). Our findings showed that patients with elevated IgE experienced significantly greater relief from pruritus following dupilumab treatment, suggesting that IgE could serve as a biomarker for identifying individuals who are more likely to benefit from treatments that target interleukin (IL)-4 and IL-13. These results support the development of personalized treatment strategies based on inflammatory profiles in patients with PN.

12 April 2024 in JID Innovations
Verified
Journal Article
Open access
ABAaron Bao
Aaron Bao
EMEmily Ma
Emily Ma
HCHannah Cornman
Hannah Cornman
AKAnusha Kambala
Anusha Kambala
JMJaya Manjunath
Jaya Manjunath
SKShawn G. Kwatra
Shawn G. Kwatra
Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intense pruritus and skin nodules. Beyond the skin, PN involves circulating blood inflammation that may contribute to systemic disease comorbidities. Dupilumab was recently approved for treatment of PN, but its effects on systemic inflammation are unknown. Thus, we aimed to characterize changes in plasma concentrations of inflammatory proteins after dupilumab treatment. In this exploratory study, plasma samples were collected from 3 patients with moderate-to-severe PN before and after ≥6 months of dupilumab treatment. All patients exhibited clinically significant improvements after treatment. Of the 2569 proteins tested, 186 were differentially expressed after treatment (q < 0.1, fold change > 1.3). Downregulated proteins included cytokines associated with T helper (Th) 1 (IFN-γ, TNF-α), Th2 (IL-4, IL-13), and Th17/Th22 (IL-6, IL-22) signaling. Markers of innate immunity (IL-19, toll-like receptor 1, nitric oxide synthase 2), immune cell migration (CCL20, CD177), and fibrosis (IL-11, IL-22) were also decreased (q < 0.1). Gene set variation analysis of Th2, Th17, and epithelial–mesenchymal transition gene sets showed reduced pathway expression in the post-treatment cohort (P < .05). Plasma cytokine levels of IL-11, nitric oxide synthase 2, IL-13, IL-4, and IFNG (R2 > 0.75, q < 0.10) showed the strongest correlations with pruritus severity. Dupilumab may reduce systemic inflammatory proteins associated with multiple immune and fibrosis pathways in patients with PN, potentially modulating the development of systemic disease comorbidities.

12 July 2024 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
OPOlivia Pierog
Olivia Pierog
ABAaron Bao
Aaron Bao
SRSima Rozati
Sima Rozati

19 February 2025 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
ABAaron Bao
Aaron Bao
SHStephen R. Hooper
Stephen R. Hooper
LSLaura M. Sterni
Laura M. Sterni
CECyd K. Eaton
Cyd K. Eaton
SRSarah Radtke
Sarah Radtke
JWJoy Wan
Joy Wan